SWOG
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1956-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.swog.org
S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: rituximabRadiation: radiation therapy
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 71
- Registration Number
- NCT00005089
- Locations
- 🇺🇸
Veterans Affairs Medical Center - West Los Angeles, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸CCOP - Atlanta Regional, Atlanta, Georgia, United States
FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00077337
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
🇺🇸CCOP - Atlanta Regional, Atlanta, Georgia, United States
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- Biological: cetuximab
- First Posted Date
- 2004-01-13
- Last Posted Date
- 2015-11-17
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 766
- Registration Number
- NCT00075686
- Locations
- 🇺🇸
Cancer Center at Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸Banner Thunderbird Medical Center, Glendale, Arizona, United States
🇺🇸CCOP - Western Regional, Arizona, Phoenix, Arizona, United States
S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer
- First Posted Date
- 2004-01-13
- Last Posted Date
- 2021-01-13
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 695
- Registration Number
- NCT00075764
- Locations
- 🇺🇸
Grant Medical Center Cancer Care, Columbus, Ohio, United States
🇺🇸Mount Carmel Health - West Hospital, Columbus, Ohio, United States
🇺🇸Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland, United States
S0310: Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Bronchoalveolar Lung Cancer
- Conditions
- Lung Cancer
- Interventions
- Biological: GVAX lung cancer vaccine
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2012-07-24
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 19
- Registration Number
- NCT00074295
S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix
- Conditions
- High-grade Squamous Intraepithelial LesionStage 0 Cervical Cancer
- First Posted Date
- 2003-11-05
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00072540
S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
- Conditions
- Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer
- Interventions
- First Posted Date
- 2003-10-15
- Last Posted Date
- 2012-10-08
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 31
- Registration Number
- NCT00014144
- Locations
- 🇺🇸
MBCCOP - Gulf Coast, Mobile, Alabama, United States
🇺🇸MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸CCOP - Atlanta Regional, Atlanta, Georgia, United States
S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Biological: pegfilgrastim
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 3294
- Registration Number
- NCT00070564
- Locations
- 🇺🇸
Saint Joseph's Hospital of Atlanta, Atlanta, Georgia, United States
🇺🇸Cancer Care Associates - Norman, Norman, Oklahoma, United States
🇺🇸Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States
S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00070434
S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: rituximabRadiation: radiation therapyBiological: Yttrium-90 ibritumomab tiuxetanBiological: Indium-111 ibritumomab tiuxetan
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 46
- Registration Number
- NCT00070018
- Locations
- 🇺🇸
Alaska Regional Hospital Cancer Center, Anchorage, Alaska, United States
🇺🇸Providence Cancer Center, Anchorage, Alaska, United States
🇺🇸CCOP - Greenville, Greenville, South Carolina, United States